By Hendra Lukman 
Stanford Medicine researchers have unveiled a revolutionary approach that completely prevented or fully reversed Type 1 diabetes in mice by transplanting both blood-forming stem cells and pancreatic islet cells from immunologically mismatched donors. This pioneering study, published in the Journal of Clinical Investigation, marks a significant leap forward in understanding and potentially treating autoimmune diseases. The findings suggest a future where Type 1 diabetes, a chronic condition characterized by the immune system’s destruction of insulin-producing cells, could become a treatable, even curable, disease.
The core of this breakthrough lies in the creation of a "hybrid immune system" within the recipient mice. Unlike traditional transplant methods that often require lifelong immunosuppression to prevent rejection, this new protocol skillfully re-educates the recipient’s immune system. This process not only enables the acceptance of donor cells but also halts the autoimmune assault on the body’s own pancreatic islets. Remarkably, none of the treated mice developed graft-versus-host disease, a serious complication where the donor immune cells attack the recipient’s tissues. Furthermore, the mice no longer required immunosuppressive drugs or insulin throughout the six-month study period, a testament to the sustained efficacy of the treatment.
"The possibility of translating these findings into humans is very exciting," stated Seung K. Kim, MD, PhD, the KM Mulberry Professor and a leading figure in developmental biology, gerontology, endocrinology, and metabolism at Stanford Medicine. Dr. Kim, who also directs the Stanford Diabetes Research Center and the Northern California Breakthrough T1D Center of Excellence, highlighted the clinical relevance of the study’s key steps. "The key steps in our study — which result in animals with a hybrid immune system containing cells from both the donor and the recipient — are already being used in the clinic for other conditions," he explained. "We believe this approach will be transformative for people with Type 1 diabetes or other autoimmune diseases, as well as for those who need solid organ transplants."
Building on a Foundation of Stem Cell and Islet Research
This latest success builds directly upon earlier work conducted by Dr. Kim and his collaborators in 2022. In that preceding study, the researchers induced diabetes in mice using toxins to eliminate insulin-producing cells. They then employed a less intensive pre-transplant preparation, involving immune-targeting antibodies and low-dose radiation, followed by a combined transplant of blood stem cells and islet cells from an unrelated donor. This earlier protocol successfully restored blood sugar control in the induced diabetic models.
However, the current study presented a more formidable challenge: addressing Type 1 diabetes, which arises from the body’s own immune system spontaneously targeting and destroying pancreatic islet cells. In human Type 1 diabetes, the immune system is already primed to attack these vital cells, making the transplanted islets face a dual threat: being recognized as foreign tissue and being targeted by a pre-existing autoimmune response.
"Just like in human Type 1 diabetes, the diabetes that occurs in these mice results from an immune system that spontaneously attacks the insulin-producing beta cells in pancreatic islets," Dr. Kim elaborated. "We need to not only replace the islets that have been lost but also reset the recipient’s immune system to prevent ongoing islet cell destruction. Creating a hybrid immune system accomplishes both goals." The inherent biological characteristics that drive autoimmune diabetes in these mouse models also complicate the preparation for blood stem cell transplantation, presenting a significant hurdle that the current research has now overcome.
A Simple Drug Tweak Unlocks Complete Diabetes Protection
The research team identified a surprisingly straightforward solution to this complex problem. By incorporating a medication commonly used in the treatment of autoimmune diseases into their established pre-transplant regimen, they achieved remarkable results. Preksha Bhagchandani, a graduate and medical student and lead author of the study, along with Stephan Ramos, PhD, a postdoctoral fellow and co-author, integrated this new medication into the protocol.
Following this adjusted protocol and subsequent blood stem cell transplantation, the mice developed a hybrid immune system, a blend of donor and recipient cells. Crucially, 100% of the mice (19 out of 19) did not develop Type 1 diabetes. In a separate cohort of mice that already had established Type 1 diabetes, a remarkable nine out of nine were fully cured after receiving the combined blood stem cell and islet cell transplant.
The significance of this finding is amplified by the fact that the antibodies, drugs, and low-dose radiation employed in this protocol are already standard components of clinical practice for blood stem cell transplantation. This existing familiarity within the medical community significantly streamlines the path toward human clinical trials for Type 1 diabetes.
From Kidney Tolerance to Hybrid Immunity: A Legacy of Innovation
The current research stands on the shoulders of decades of foundational work by Stanford investigators, particularly the late Samuel Strober, MD, PhD, a distinguished professor of immunology and rheumatology, and his colleagues, including study co-author Judith Shizuru, MD, PhD, a professor of medicine. Their pioneering research demonstrated that bone marrow transplants from partially immunologically matched human donors could induce a hybrid immune system in recipients. This breakthrough enabled the long-term acceptance of kidney transplants from the same donor without the need for continuous immunosuppressive drugs, with some patients maintaining stable kidney function for decades.
Blood stem cell transplants are a well-established treatment for various blood and immune system cancers, such as leukemia and lymphoma. However, in oncology, these procedures typically involve high-dose chemotherapy and radiation to eradicate the patient’s original blood and immune system, often leading to severe side effects. Dr. Shizuru and her team have been instrumental in developing a safer, less intensive conditioning regimen for patients with non-cancerous conditions like Type 1 diabetes. This approach aims to reduce bone marrow activity just enough to allow donor blood stem cells to engraft and proliferate, thereby minimizing risks.
"Based on many years of basic research by us and others, we know that blood stem cell transplants could also be beneficial for a wide range of autoimmune diseases," Dr. Shizuru commented. "The challenge has been to devise a more benign pre-treatment process, diminishing risk to the point that patients suffering from an autoimmune deficiency that may not be immediately life-threatening would feel comfortable undergoing the treatment."
The current study addresses this challenge by leveraging the immune-reprogramming capabilities of transplanted blood stem cells. "Now we know that the donated blood stem cells re-educate the recipient animal’s immune system to not only accept the donated islets, but also not attack its healthy tissues, including islets," Dr. Kim explained. "In turn, the donated blood stem cells and the immune system they produce learn to not attack the recipient’s tissues, and graft-versus-host disease can be avoided." This elegant mechanism of mutual tolerance is the cornerstone of the observed success.
Navigating Future Hurdles for Type 1 Diabetes Treatment
While the results in mice are undeniably promising, several significant obstacles must be overcome before this groundbreaking strategy can be widely implemented for treating Type 1 diabetes in humans. A primary challenge is the current scarcity of pancreatic islets, which are exclusively obtained from deceased donors. Furthermore, the blood stem cells must originate from the same individual as the islets, adding another layer of complexity to donor matching. The sufficiency of islet cells typically recovered from a single donor to reverse established Type 1 diabetes in humans also remains an open question.
The research team is actively pursuing innovative solutions to address these limitations. One promising avenue involves the laboratory production of large quantities of functional islet cells from pluripotent human stem cells. Another area of investigation focuses on developing methods to enhance the survival and efficiency of transplanted donor islets post-transplantation.
Beyond Type 1 diabetes, Dr. Kim, Dr. Shizuru, and their collaborators are optimistic about the broader applicability of their gentle pre-conditioning strategy. They envision its potential to revolutionize the treatment of other autoimmune diseases, such as rheumatoid arthritis and lupus, as well as non-cancerous blood disorders like sickle cell anemia, for which current blood stem cell transplant methods remain particularly harsh. The strategy also holds promise for facilitating transplants of mismatched solid organs.
"The ability to reset the immune system safely to permit durable organ replacement could rapidly lead to great medical advances," Dr. Kim concluded, underscoring the transformative potential of this research.
The study received substantial funding from the National Institutes of Health (grants T32 GM736543, R01 DK107507, R01 DK108817, U01 DK123743, P30 DK116074 and LAUNCH 1TL1DK139565-0), the Breakthrough T1D Northern California Center of Excellence, Stanford Bio-X, the Reid Family, the H.L. Snyder Foundation and Elser Trust, the VPUE Research Fellowship at Stanford, and the Stanford Diabetes Research Center. These diverse sources of support highlight the collaborative and multi-faceted nature of this critical scientific endeavor.
